Everolimus Tablet
Product Images NDC 72603-255

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Everolimus (NDC 72603-255). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northstar Rxllc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Principal Display Panel Package Label 10 mg (10 mg Bottle Label)

Principal Display Panel Package Label 10 mg (10 mg Bottle Label)
Each tablet contains Everolimus, USP 10 mg for oral use. This medication is stored at a temperature range of 20° to 25°C (68° to 77°F), with excursions permitted to 15° to 30°C (59° to 86°F). The tablets should be stored in the original container, protected from light and moisture. This package is child-resistant and contains 30 tablets. The medication is manufactured by Biocon Pharma Limited in Bengaluru, India, and is distributed by Northstar Rx LLC in Memphis, TN.*
FDA Label Image

Principal Display Panel Package Label 2.5 mg (2.5 mg Bottle Label)

Principal Display Panel Package Label 2.5 mg (2.5 mg Bottle Label)
This is a description of a medication containing Everolimus, USP 2.5 mg in each tablet for oral use. The dosage information is available in the package insert. It is advised to store the tablets at 20° to 25°C (68° to 77°F) with excursions permitted to 15° to 30°C (59° to 86°F). The tablets should be stored in the original container, protected from light and moisture. It is important to keep this medication and all drugs out of the reach of children. The packaging is child-resistant and the expiration date is 06/2024. The tablets are manufactured by Biocon Pharma Limited in Bengaluru, India, and distributed by Northstar Rx LLC in Memphis, TN.*
FDA Label Image

Principal Display Panel Package Label 5 mg (5 mg Bottle Label)

Principal Display Panel Package Label 5 mg (5 mg Bottle Label)
This is a description of Everolimus tablets containing 5 mg of Everolimus USP. The package includes 30 tablets intended for oral use. The tablets should be stored at a temperature between 20°C to 25°C with allowable excursions to 15°C to 30°C and protected from light and moisture. The medicine should be kept out of reach of children and stored in the original container. The package is child-resistant and was issued in June 2024. The tablets are manufactured by Biocon Pharma Limited in Bengaluru, India, and distributed by Northstar Rx LLC based in Memphis, TN.*
FDA Label Image

Principal Display Panel Package Label 7.5 mg (7.5 mg Bottle Label)

Principal Display Panel Package Label 7.5 mg (7.5 mg Bottle Label)
This is a description of Everolimus tablets containing 7.5 mg of Everolimus, USP. The package includes 30 tablets and is child-resistant. The recommended storage temperature is between 20°C to 25°C. The tablets are for oral use, and detailed dosage instructions can be found in the package insert. The tablets are to be stored in their original container, protected from light and moisture. The manufacturer is Biocon Pharma Limited in Bengaluru, India, and the product is manufactured for Northstar Rx LLC in Memphis, TN.*
FDA Label Image

Everolimus Structural Formula (Everolimus Structure)

Everolimus Structural Formula (Everolimus Structure)
FDA Label Image

Figure 1: Kaplan-meier Progression-free Survival Curves (investigator Radiological Review) (Fig 1)

Figure 1: Kaplan-meier Progression-free Survival Curves (investigator Radiological Review) (Fig 1)
The text provides information on the progression-free survival probability for Everolimus 10mg with exemestane compared to Placebo with exemestane. The Kaplan-Meier medians for Everolimus 10mg with exemestane is 7.8 months, while for Placebo with exemestane, it is 32 months. The Logrank p-value is less than 0.0001, indicating a statistically significant difference. The data also includes the number of censoring times for both groups (Everolimus 10mg - exemestane: 310/485, Placebo - exemestane: 200/239) along with a graph showing the progression over time in months. It provides valuable insights into the survival outcomes of the two treatments.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.